Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 7/20 | 0.67 |
| ▸ | NR3C1 | P04150 | 13/20 | 0.63 |
| ▸ | PGR | P06401 | 11/20 | 0.63 |
| ▸ | ESR1 | P03372 | 3/20 | 0.56 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.56 |
| ▸ | THRA | P10827 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10399827 | 1.00 | AR (0.67) | ARNR3C1PGRESR1NR3C2 | |
| SCHEMBL4664713 | 1.00 | AR (0.67) | ARNR3C1PGRESR1NR3C2 | |
| SCHEMBL15094157 | 1.00 | AR (0.67) | ARNR3C1PGRESR1NR3C2 | |
| SCHEMBL9146687 | 0.94 | AR (0.58) | ARNR3C1PGRESR1NR3C2 | |
| SCHEMBL14656547 | 0.92 | AR (0.57) | ARNR3C1PGRESR1NR3C2 | |
| SCHEMBL9740103 | 0.92 | AR (0.57) | ARNR3C1PGRESR1NR3C2 | |
| SCHEMBL14666086 | 0.92 | AR (0.57) | ARNR3C1PGRESR1NR3C2 | |
| SCHEMBL20235298 | 0.92 | AR (0.57) | ARNR3C1PGRESR1NR3C2 | |
| SCHEMBL5395107 | 0.92 | AR (0.71) | ARNR3C1PGRESR1NR3C2 | |
| SCHEMBL5395109 | 0.92 | AR (0.71) | ARNR3C1PGRESR1NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9814730-B2 | Pharmaceutical composition or group of compositions for inhibiting autocrine HCG production in adult human cells | FLAMINA HOLDING AG (CH) | 2017-11-14 | — | — | US | claimed |
| US-20170143739-A1 | PHARMACEUTICAL COMPOSITION OR GROUP OF COMPOSITIONS FOR INHIBITING AUTOCRINE HCG PRODUCTION IN ADULT HUMAN CELLS | FLAMINA HOLDING AG (CH) | 2017-05-25 | — | — | US | claimed |
| US-9603856-B2 | Pharmaceutical composition or group of compositions for inhibiting autocrine HCG production in adult human cells | FLAMINA HOLDING AG (CH) | 2017-03-28 | — | — | US | claimed |
| US-20150126482-A1 | PHARMACEUTICAL COMPOSITION OR GROUP OF COMPOSITIONS FOR INHIBITING AUTOCRINE HCG PRODUCTION IN ADULT HUMAN CELLS | FLAMINA HOLDING AG (CH) | 2015-05-07 | — | — | US | claimed |
| EP-2868322-A1 | A composition or group of compositions for use in a method for inhibiting autocrine HCG production in adult human cells | Flamina Holding AG (CH) | 2015-05-06 | — | — | EP | claimed |
| EP-2868323-A1 | A pharmaceutical composition or group of compositions for inhibiting autocrine HCG production in adult human cells | Flamina Holding AG (CH) | 2015-05-06 | — | — | EP | claimed |
| US-7297702-B2 | Contraception method using competitive progesterone antagonists and novel compounds useful therein | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-11-20 | — | — | US | claimed |
| US-20050026885-A1 | Contraception method using competitive progesterone antagonists and novel compounds useful therein | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-02-03 | — | — | US | claimed |
| US-6790853-B2 | SIDE EFFECT REDUCTION; HORMONE INHIBITOR | SCHERING AG (DE) | 2004-09-14 | — | — | US | claimed |
| US-20030191102-A1 | Contraception method using competitive progesterone antagonists and novel compounds useful therein | SCHERING AG (DE) | 2003-10-09 | — | — | US | claimed |
| US-6608074-B2 | Administering during follicular phase of female menstrual cycle and in luteal phase, a competitive progesterone antagonist, which is less than an ovulation-inhibiting dose and less than an abortion-inductive dose | SCHERING AG (DE) | 2003-08-19 | — | — | US | claimed |
| EP-0639970-B2 | CONTRACEPTION METHOD USING COMPETITIVE PROGESTERONE ANTAGONISTS AND NOVEL COMPOUNDS USEFUL THEREIN | SCHERING AG (DE) | 2002-11-06 | — | — | EP | claimed |
| US-20020058649-A1 | Contraception method using competitive progesterone antagonists and novel compounds useful therein | SCHERING AG (DE) | 2002-05-16 | — | — | US | claimed |
| US-6340688-B1 | ADMINISTERING TO FEMALE DURING MENSTRUAL CYCLE AMOUNT OF COMPETITIVE PROGESTERONE ANTAGONIST WHICH IS LESS THAN OVULATION-INHIBITING DOSE AND LESS THAN ABORTION-INDUCTIVE DOSE | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-01-22 | — | — | US | claimed |
| EP-0639970-B1 | CONTRACEPTION METHOD USING COMPETITIVE PROGESTERONE ANTAGONISTS AND NOVEL COMPOUNDS USEFUL THEREIN | SCHERING AG (DE) | 1998-01-28 | — | — | EP | claimed |
| US-5439913-A | 11B,19-(4-(Cyanophenyl)-o-phenylene)-17B-hydroxy-17a-(3-hydroxyprop -1(Z)-enyl)-4-androsten-3-one or 11B,19-(4-(3-pyridinyl)-o-phenylene)-17B-hydroxy-17a-(3-hydroxyprop-1(Z) -enyl)-4-androsten-3-one | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-08-08 | — | — | US | claimed |
| US-9814730-B2 | Pharmaceutical composition or group of compositions for inhibiting autocrine HCG production in adult human cells | FLAMINA HOLDING AG (CH) | 2017-11-14 | — | — | US | disclosed |
| US-20170143739-A1 | PHARMACEUTICAL COMPOSITION OR GROUP OF COMPOSITIONS FOR INHIBITING AUTOCRINE HCG PRODUCTION IN ADULT HUMAN CELLS | FLAMINA HOLDING AG (CH) | 2017-05-25 | — | — | US | disclosed |
| EP-0262188-B1 | STEROIDS COMPRISING A SPIRANIC CYCLE IN POSITION 17, PREPARATION PROCESS AND UTILIZATION THEREOF | ROUSSEL-UCLAF (FR) | 1990-11-14 | — | — | EP | disclosed |
| US-4900725-A | CONTRACEPTIVES | ROUSSEL UCLAF (FR) | 1990-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026885-A1 | Contraception method using competitive progesterone antagonists and novel compounds useful therein | PGR, PGRMC1, HSD17B11 | AR 220/4885NR3C1 47/4885PGR 1/4885 |
| US-20020058649-A1 | Contraception method using competitive progesterone antagonists and novel compounds useful therein | PGR, PGRMC1, PGRMC2 | AR 313/4885NR3C1 45/4885PGR 1/4885 |
| US-20030191102-A1 | Contraception method using competitive progesterone antagonists and novel compounds useful therein | PGR, PGRMC1, PGRMC2 | AR 313/4885NR3C1 45/4885PGR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.